Literature DB >> 797286

Production of osteoclast-activating factor by normal human peripheral blood rosetting and nonrosetting lymphocytes.

P Chen, C Trummel, J Horton, J J Baker, J J Oppenheim.   

Abstract

This study has tested the ability of human mononuclear cells and the subpopulations of lymphocytes that rosette (E-RFC) or do not rosette (non-E-RFC) with sheep red blood cells to synthesize DNA and to produce a mediator with bone resorbing activity (osteoclast-activating factor, OAF) in response to stimulation with phytohemagglutinin (PHA). Mononuclear cells were stimulated by PHA both to synthesize DNA and to produce a factor that caused bone resorption. E-RFC enriched for T lymphocytes and depleted of macrophages synthesized considerable DNA in response to stimulation with PHA, but were unable to produce significant bone resorbing activity in tissue culture unless macrophages were re-added to the E-RFC. In contrast, mononuclear cells depleted of E-RFC (non-E-RFC enriched for B cells) did not synthesize DNA in response to stimulation with PHA, but did produce a mediator that caused significant bone resorption in tissue culture. In most of the experiments, unstimulated non-E-RFC produced as much OAF as the PHA-stimulated non-E-RFC. These results suggest that both activated T lymphocytes (E-RFC) and B lymphocytes (non-E-RFC) can produce OAF.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 797286     DOI: 10.1002/eji.1830061014

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

1.  A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner.

Authors:  Leonard Rifas; M Neale Weitzmann
Journal:  Arthritis Rheum       Date:  2009-11

2.  Angioimmunoblastic lymphadenopathy and hypercalcaemia.

Authors:  M J Sworn; R Buchanan; D A McGill
Journal:  J Clin Pathol       Date:  1979-10       Impact factor: 3.411

3.  Identification and distribution of immunocompetent cells in inflamed gingiva of human chronic periodontitis.

Authors:  H Okada; T Kida; H Yamagami
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

4.  Polyclonal B-cell activation induced by extracts of Gram-negative bacteria isolated from periodontally diseased sites.

Authors:  P H Bick; A B Carpenter; L V Holdeman; G A Miller; R R Ranney; K G Palcanis; J G Tew
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

5.  1 alpha,25-dihydroxyvitamin D3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism.

Authors:  E Abe; C Miyaura; H Tanaka; Y Shiina; T Kuribayashi; S Suda; Y Nishii; H F DeLuca; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

6.  Spontaneous production of thymocyte-activating factor by human gingival fibroblasts and its autoregulatory effect on their proliferation.

Authors:  Y Ohmori; S Hanazawa; S Amano; T Miyoshi; K Hirose; S Kitano
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

7.  Nonspecific induction of immunoglobulin M antibodies to periodontal disease-associated microorganisms after polyclonal human B-lymphocyte activation by Fusobacterium nucleatum.

Authors:  D F Mangan; T Won; D E Lopatin
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

8.  Polyclonal activation of human peripheral blood B lymphocytes by Fusobacterium nucleatum.

Authors:  D F Mangan; D E Lopatin
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

9.  Thymus-derived lymphocytes and their interactions with macrophages are required for the production of osteoclast-activating factor in the mouse.

Authors:  M Horowitz; A Vignery; R K Gershon; R Baron
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

10.  Release of the lymphokine osteoclast activating factor requires cyclic AMP accumulation.

Authors:  T Yoneda; G R Mundy
Journal:  Calcif Tissue Int       Date:  1982-03       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.